Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastro-enteropancreatic Neuroendocrine Tumor

Interventions

DRUG: Lutathera
DRUG: 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)
DRUG: 2.5% Lys-Arg sterile amino acid solution
DRUG: High dose 60 mg octreotide long-acting repeatable

Sponsor

Advanced Accelerator Applications